Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of WVE-210201 With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy (DYSTANCE 51)

NCT03907072 is registered in ClinicalTrials.gov with Wave Life Sciences USA, Inc. as lead sponsor.

NCT NCT03907072
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03907072 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of WVE-210201 With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy (DYSTANCE 51)
Lead sponsor
Wave Life Sciences USA, Inc.
Phase
Phase 2/3
Overall status
Terminated
Start date
September 4, 2019
Completion date
January 9, 2020
Enrollment
6 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy